Credit Suisse reiterated coverage on ATAI Life Sciences with a new price target
$ATAI
Biotechnology: Pharmaceutical Preparations
Health Care
Credit Suisse reiterated coverage of ATAI Life Sciences with a rating of Outperform and set a new price target of $24.00 from $25.00 previously